Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agenus Receives Second Milestone Payment from Merck
https://markets.businessinsider.com/news/stocks/agenus-receives-second-milestone-payment-from-merck-1027461963
Sometimes we have to ask ourself, IF Dan and Lombardo couldn't make a deal, how Ken could make a deal? He came from a bankrupt company, Does he has connections or ability to negotiate and make some deals? I just hope we don't face the worst, (out of cash and new dilution), hope ken not going to make Advaxis another Rosetta Genomics!
If we don't hear anything before Sep CC, i have bad feeling, we may face big problem with Cash. NO deal, No Cash. No matter what good science you have, company going to die. Hope KEN have some solutions ASAP!
ONCS is trading at $1.60 now, Slap face on Advaxis!
Is it possible from another BP, could be another collaboration with share purchase. if that was the case, we will hear it soon with new partnership deal signing.
Not much buying and selling if you check Institu ownership, where did all those 7 million shares went, who took them?
https://fintel.io/sos/us/adxs
Now I'm 100% positive KEN did ATM offering last month, 10 million shares for sure.
Yes Joseph Edelman is out of Advaxis according to new SEC filing, BLUE check May holding VS Aug holding
https://www.sec.gov/Archives/edgar/data/1224962/000101297518000425/xslForm13F_X01/infotable.xml
https://www.sec.gov/Archives/edgar/data/1224962/000101297518000425/xslForm13F_X01/infotable.xml
Why so rush keith?wait until next year for 5 billion
just found out, have two account, one for trading, one account own money on margin, fck!
Got a call from Etrade ask me if i want to sell advaxis shares, very strange. anybody got call? very strange.
how about 13?
Sunday thoughts:
1. higher risk, higher return
2. no one on this board could manipulate the stock price
3. if you believe the science, no regret bought this stock
4. Stock price will raise with right time, right news.
5. Amgen and other BPs knew what they are doing, stay with their focus.
6. Everybody is greedy, no one to blame, just blame yourself!
7. Looking forward, dont' look back what happend!
Anybody read chinese? What it say? tks!
http://www.hkioc.com.hk/zh/article/1920
Either Amgen is taking HOT or some other BP is taking it! If Amgen is taking it, basically they almost own the whole company. Better to acquire Advaxis instead of sign another HOT deal. If another BP is taking HOT, it will create a conflict situation for Amgen. Either way is good! Let the show begin. IMO
$2-3 billion is piece cake for Amgen, they would rather spend $5-6 billion when good data meet their expectation instead of $2-3 billion with unsure things in the dark!
What date is the CC?
Talking about Disaster and bad luck, AMPE is a penny stock now in two days, WOW! Bad news from FDA and then stock offering news. You really don't want Advaxis fell in that situation! Hope Ken don't disappoint shareholders!
PPS Racing between ONCS & ADXS! If Dan sign another deal with money and Ken didn't sign any deals, that would be slap on the face of BOD and KEN!
Companies Involved in Neoantigen Therapy Development
https://bblsa.com/wp-content/uploads/2018/06/Companies-involved-in-neoantigen-therapy-development.pdf
We could see good news before September CC or bad news at the CC!
If we have a partner for AXAL and some good money, then Avaxis is ready to rock again with HOT deals on the way. I can see $30 pps again.
If we have bad news, you can dump it or turn off your computer!
No news is good news!
6th outcome company sold! LOL
Or we may screwed by KEN again! Remember we didn't get any good news for the last two year at CC!
you are correct, that was my earliest prediction. could be early or later. Maybe HOT later.
What's going to happen in September CC?
four possible outcomes
1.Partnership AXAL with upfront money, deals with HOT and upfront money
2. No partnership found for AXAL, AIM2SERV dropped, Deals with hot and
upfront money.
3. Partnership AXAL with upfront money, no deal with HOT
4. No partner for AXAL, No deal for HOT. Announcing dilution!
AMPE Ampio Pharmaceuticals, Inc is over!
This chinese guy is gone too! I'm happy to see all these people left! waste of money to hire all these people!
https://www.linkedin.com/in/xin-du-01a0271b/
If you check linkedin, more and more employees got Axed, is it a good sign or bad sign? this lady was at advaxis before, now she is gone to spark
https://www.linkedin.com/in/fatimaahmadpharmd/
Is it legal this way?
More employees laid off, running cash very low, can Ken make it through June 2019?
Could KEN give us surprise in September CC? good or bad. Almost 95% was bad CC last two years. Long term shareholders should prepare for the worst if no deals or cash raised! Advaxis always surprise us with bad news at CC! Could Ken change it this time? Lets wait and see!
I just don't want see this with Advaxis! Rosetta Genomics Files for Chapter 7 Bankruptcy
Jun 04, 2018 | staff reporter
NEW YORK (GenomeWeb) – Rosetta Genomics last week filed for Chapter 7 bankruptcy, just one day after disclosing that its planned merger with Genoptix was in trouble.
Late last year, Genoptix agreed to acquire Rosetta for $10 million in cash, but that deal failed to garner enough support from Rosetta shareholders. The companies later signed another merger agreement that valued Rosetta at $9 million and was ultimately approved by Rosetta's investors.
While the transaction was slated to close on May 27, Rosetta said on May 30 that Genoptix had "refused to provide assurances that it intends to complete the transaction" due to an undisclosed "material adverse effect" affecting Rosetta, as well as breaches of representations and warranties.
Rosetta disputed Genoptix's claims, and said that it would file for bankruptcy protection if the merger was not consummated. According to documents filed with the US Bankruptcy Court for the District of Delaware, Rosetta filed for Chapter 7 bankruptcy on May 31.
Under Chapter 7 bankruptcy, a company seeks to liquidate its assets. Among Rosetta's listed creditors are Agilent Technologies, Fisher Scientific, Integrated DNA Technologies, and Sigma Aldrich.
Rosetta had offices in Israel and New Jersey and developed and commercialized microRNA-based diagnostic tests for various cancers. During the past year, the company underwent a series of strategic moves as its business struggled. In September, it announced layoffs as part of a plan to trim $1.7 million in expenses. It also agreed to sell its PersonalizeDx unit for $2.9 million.
The company also found itself in trouble with the Nasdaq for failing to meet certain listing requirements.
We have news today? what news? I don't see it
Conflict between the two!
Remember NEO includes Lung cancer, now HOT first is lung cancer too! No matter what kind of lung cancer, doesn't make sense to me!
I think KEN did ATM offering last month!
The reason why NSCLC for HOT, you have to read this article.
Fourteen Years After Lung Cancer Diagnosis, Patient is Enjoying Her Life
http://www.hadassah.org/news-stories/lung-cancer.html
Her family doctor missed it the first time. The dry cough, the tiredness -probably an allergy or a virus, he thought. She guessed it might be menopause or the sadness over losing her mother with whom she was close. Nonetheless, Ofra Tempkin was looking forward to her 50th birthday. Her many friends and family were making a special party. But before the party, she and her husband Zeev, a city planner, took a short vacation to Tuscany. "I couldn't finish a sentence without coughing," she said. “Zeev insisted that as soon as we got back I was going to have a chest x-ray. Maybe I had pneumonia." It was worse.
The doctor set up an immediate appointment with Dr. Uzi Yizhar at Hadassah Hospital. "He said it was serious. A 99 percent chance that I had lung cancer. All I could think of was, 'the poor doctor who has to tell people this bad news.' My own defense mechanism wouldn't let me absorb that I had just heard very bad news." Lung cancer is the number one cause of death from cancer for both men and women. Like Ofra, most patients are diagnosed late. She was already stage 4, with no better than a two percent chance of surviving five years, according to statistics.
Tempkin was already worried about how her son and daughter, then in high school, were going to serve in the IDF and get though their adolescence without a mom. But Prof. Tamar Peretz, whom Dr. Yitzhar called in immediately on this case, took Ofra aside. "Forget about statistics," she said. "You are a hundred percent a young woman with low cholesterol, no diabetes-except for the cancer you are healthy."
"I didn't realize it at the time, "says Tempkin, "But I was experiencing what personalized medicine is all about."
Ofra Tempkin was born in Tel Aviv, the daughter of a father from White Russia and a mother from Bulgaria. Both parents smoked. Her father died at 58, less than a year after being diagnosed with lung cancer. Her mother died of Alzheimer's' disease. After studying sociology and anthropology at Tel Aviv University, Tempkin worked for Israel's nature society, where she met and fell in love with city planner Zeev Tempkin, a former kibbutznik, divorced with two daughters. Zeev smoked for much of the marriage but gave it up. Ofra Tempkin had never smoked. "My circle of friends and family heard immediately of my diagnosis because we cancelled the party. We never sat the kids down for a family meeting to tell them, the way they do in books. My daughter asked me if I had "a cancerous tumor I don't know where she got that term, but we all began to use it. It wasn't that I had cancer, the tumor did."
Treatment began with chemotherapy, which shrunk the tumor. "I hated losing my hair," said Tempkin, today with red hair and big green eyes. "It was winter, and I wore hats and wigs, and wondered how I could go on. " That was the winter of 2002-3, but Tempkin was indifferent to the terror attacks around her. "I felt as if I had an intifada inside of me." After a year, she was offered Iressa, (Gefitinib). "Today, there are genetic tests to see if this is a good match for a patient. Back then, it was thought at Hadassah to be good for non-smoking women and it worked well for me." She took it for two years.
The pain in her pelvis turned out to be a secondary cancer site in her hip. Tempkin underwent radiation, and another course of chemotherapy. "My team expanded, and now Prof. Nehushtan was working together with Prof. Peretz. I'm not one of those persons who says 'I hate hospitals.' I like the doctors and nurses at Hadassah. I feel as if it is my second home, sort of like a place of work. I developed deep personal connections with the staff the way one does with co-workers."
In 2008, Tempkin was a year beyond the five-year survival measure, but she still had lung cancer. As it happens, clinical trials were going on at Hadassah using the Listeria bacteria as a cancer vaccine, taking advantage of the bacteria's ability to induce immunity. Although there was no clinical proof that it could impede metastasizing lung cancer, Tempkin was able to get the vaccine on a compassionate basis, through the connections of the Hadassah researchers. It worked for her. "We can't prove why it worked for her and not other patients," said Dr. Nechushtan. "The vaccine may have improved her body's response to more traditional cancer treatment." In Israel, the listeria vaccine was only available at Hadassah Hospital.
She's still in treatment. "At every juncture, a solution was found for my problem." Says Tempkin. "My life is full of joy. We’ve travelled to Japan and Argentina. I've seen my children grow up and marry. I have beautiful grandchildren.” Zeev's business is largely Tel Aviv based these days, but Ofra won't hear of moving. "I have to be near home, my second home-Hadassah."
If HOT is so effective, safe, low cost, Amgen should act fast to acquire Advaxis and don't let other BPs to take it.
If I were the CEO of Amgen, I would buy it right now with $3-4billion. If you do the caculation, at the end, Amgen is not paying anything from pocket. They can get $500million each construct with collaboration other BPs. Simple like that!
I just don't think Amgen will let HOT go like that! If you have the money, why buy part of it and let your competitor to take another part to kill you! don't make sense to me!